Enlivex Therapeutics (ENLV) SEC Filings & 10K Form

$1.40
0.00 (0.00%)
(As of 05/17/2024 ET)

Recent Enlivex Therapeutics SEC Filings

DateFilerForm TypeView
04/29/2024
7:01 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/22/2024
7:02 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2024
7:00 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2024
7:13 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/29/2024
3:30 PM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/07/2024
7:02 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/22/2024
7:00 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/17/2024
7:02 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2023
7:01 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/07/2023
3:30 PM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
3:30 PM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2023
7:00 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/13/2023
3:42 PM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2023
7:00 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2023
3:30 PM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/02/2023
7:05 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/31/2023
7:05 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2023
7:03 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2023
7:09 AM
Enlivex Therapeutics Ltd. (Filer)
Enlivex Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:ENLV) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners